2026 Press Releases 2026 2025 2024 2023 2022 Portfolio Companies New Leaf Portfolio Companies Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private PlacementJune 1, 2026 Edgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular PipelineJune 1, 2026 MemorialCare Heart & Vascular Institute Becomes First Hospital in Los Angeles County to Offer Cleerly AI-Powered Heart Disease Analysis, Quantifying Total Plaque Volume and Soft PlaqueMay 20, 2026 Bluesight Launches Prism, an AI Platform Built for Health Systems, Debuting with Prism AssistantMay 12, 2026 Electra Therapeutics Announces First Patient Dosed in Phase 1 Study of Ipsoprubart (ELA026) in T Cell MalignanciesMay 5, 2026 STAR THERAPEUTICS RECEIVES FDA RARE PEDIATRIC DISEASE AND BREAKTHROUGH THERAPY DESIGNATIONS FOR VGA039 IN VON WILLEBRAND DISEASE PROPHYLAXISApril 21, 2026 Cleerly AI-QCT Demonstrates High Agreement With Invasive IVUS in INVICTUS RegistryMarch 20, 2026 Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 DaysMarch 18, 2026 Qlaris Bio Appoints Fred Guerard, Pharm.D., as President and Chief Executive OfficerMarch 10, 2026 Flosonics Medical Receives Vizient Innovative Technology Contract for FloPatch Wearable Doppler UltrasoundMarch 3, 2026 Rallybio Corporation and Candid Therapeutics Announce Merger AgreementMarch 2, 2026 Havas Health and BrightInsight Forge Exclusive Alliance to Tackle Pharma’s $500B+ Patient ProblemFebruary 26, 2026 TigerConnect Launches AI-Powered Operator Console To Modernize Hospital CommunicationsFebruary 23, 2026 Aetna Approves Coverage for Cleerly’s AI Cardiovascular Imaging AnalysisJanuary 6, 2026
